Abstract
The sequence of the cloned mammalian kappa opioid receptor, a receptor that might play a key role in the development of non-addictive analgesic agents, has been patented by the US-based Adolor Corporation. The exclusive worldwide licence gives Adolor sole access to develop further pharmaceuticals tools aimed at this receptor, as well as related opioid receptor technologies. Adolor's lead compounds, currently in Phase II/III clinical trials for the alleviation of visceral pain in pancreatitis or postoperative ileus, target peripheral opioid receptors without causing the addictive side-effects of classical opioid narcotics. DC
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
